FibroBiologics Inc. Announces Upcoming Phase 1/2 Clinical Trial for Diabetic Foot Ulcer Treatment Using Fibroblast-Based Therapies at BIO International Convention 2025

Reuters

2025/06/16

<a href="https://laohu8.com/S/FBLG">FibroBiologics</a> Inc. Announces Upcoming Phase 1/2 Clinical Trial for Diabetic Foot Ulcer Treatment Using Fibroblast-Based Therapies at BIO International Convention 2025

FibroBiologics Inc. (Nasdaq: FBLG), a clinical-stage biotechnology company, has announced an upcoming presentation at the BIO International Convention 2025. The presentation, scheduled for June 17, 2025, will be delivered by the company's Founder and CEO, Pete O'Heeron, in Boston, MA. It will cover recent corporate milestones and research developments utilizing fibroblast-based technology for conditions such as wound healing, multiple sclerosis, and psoriasis. Notably, the company is preparing to initiate a Phase 1/2 clinical trial later this year, focusing on wound healing in diabetic foot ulcers. This trial aims to explore the potential of fibroblast-based therapies to address underlying biological dysfunctions in chronic diseases. Results from this clinical trial have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9469277-en) on June 16, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2543460338"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2543460338\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2543460338?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-16 21:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2543460338","market":"fut","top_or_hot":-1,"title":"FibroBiologics Inc. Announces Upcoming Phase 1/2 Clinical Trial for Diabetic Foot Ulcer Treatment Using Fibroblast-Based Therapies at BIO International Convention 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/FBLG\">FibroBiologics</a> Inc. Announces Upcoming Phase 1/2 Clinical Trial for Diabetic Foot Ulcer Treatment Using Fibroblast-Based Therapies at BIO International Convention 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        FibroBiologics Inc. (Nasdaq: FBLG), a clinical-stage biotechnology company, has announced an upcoming presentation at the BIO International Convention 2025. The presentation, scheduled for June 17, 2025, will be delivered by the company's Founder and CEO, Pete O'Heeron, in Boston, MA. It will cover recent corporate milestones and research developments utilizing fibroblast-based technology for conditions such as wound healing, multiple sclerosis, and psoriasis. Notably, the company is preparing to initiate a Phase 1/2 clinical trial later this year, focusing on wound healing in diabetic foot ulcers. This trial aims to explore the potential of fibroblast-based therapies to address underlying biological dysfunctions in chronic diseases. Results from this clinical trial have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9469277-en) on June 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FibroBiologics Inc. Announces Upcoming Phase 1/2 Clinical Trial for Diabetic Foot Ulcer Treatment Using Fibroblast-Based Therapies at BIO International Convention 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFibroBiologics Inc. Announces Upcoming Phase 1/2 Clinical Trial for Diabetic Foot Ulcer Treatment Using Fibroblast-Based Therapies at BIO International Convention 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-16 21:50</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/FBLG\">FibroBiologics</a> Inc. Announces Upcoming Phase 1/2 Clinical Trial for Diabetic Foot Ulcer Treatment Using Fibroblast-Based Therapies at BIO International Convention 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        FibroBiologics Inc. (Nasdaq: FBLG), a clinical-stage biotechnology company, has announced an upcoming presentation at the BIO International Convention 2025. The presentation, scheduled for June 17, 2025, will be delivered by the company's Founder and CEO, Pete O'Heeron, in Boston, MA. It will cover recent corporate milestones and research developments utilizing fibroblast-based technology for conditions such as wound healing, multiple sclerosis, and psoriasis. Notably, the company is preparing to initiate a Phase 1/2 clinical trial later this year, focusing on wound healing in diabetic foot ulcers. This trial aims to explore the potential of fibroblast-based therapies to address underlying biological dysfunctions in chronic diseases. Results from this clinical trial have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9469277-en) on June 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250616:nNDL11D5c2:1","article_id":"2543460338","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2543460338","pubTimestamp":1750081857,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"FibroBiologics Inc. Announces Upcoming Phase 1/2 Clinical Trial for Diabetic Foot Ulcer Treatment Using Fibroblast-Based Therapies at BIO International Convention 2025. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via GlobeNewswire  on June 16, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","FBLG":"FibroBiologics","BK4585":"ETF&股票定投概念","BK4588":"碎股","NDAQ":"纳斯达克OMX交易所","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4112":"金融交易所和数据","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD"},"translate_title":"FibroBiologics Inc.在2025年BIO国际大会上宣布即将进行使用成纤维细胞疗法治疗糖尿病足溃疡的1/2期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"FBLG":0.9},"content_text":"FibroBiologics Inc. Announces Upcoming Phase 1/2 Clinical Trial for Diabetic Foot Ulcer Treatment Using Fibroblast-Based Therapies at BIO International Convention 2025\n    \n\n        FibroBiologics Inc. (Nasdaq: FBLG), a clinical-stage biotechnology company, has announced an upcoming presentation at the BIO International Convention 2025. The presentation, scheduled for June 17, 2025, will be delivered by the company's Founder and CEO, Pete O'Heeron, in Boston, MA. It will cover recent corporate milestones and research developments utilizing fibroblast-based technology for conditions such as wound healing, multiple sclerosis, and psoriasis. Notably, the company is preparing to initiate a Phase 1/2 clinical trial later this year, focusing on wound healing in diabetic foot ulcers. This trial aims to explore the potential of fibroblast-based therapies to address underlying biological dysfunctions in chronic diseases. Results from this clinical trial have not yet been presented.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9469277-en) on June 16, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}